Pirlindole

Pirlindole
Systematic (IUPAC) name
	8-methyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole
Clinical data
Trade names	Pirazidol
Legal status	℞ (Prescription only);
Routes of; administration	Oral
Pharmacokinetic data
Bioavailability	20–30%
Protein binding	95%
Metabolism	hepatic
Onset of action	2 to 8 hours
Biological half-life	185 hours
Excretion	urine (50–70%), feces (25–45%)
Identifiers
CAS Number	60762-57-4
ATC code	None
PubChem	CID: 68802
IUPHAR/BPS	6638
DrugBank	DB09244
ChemSpider	62039
UNII	V39YPH45FZ
KEGG	D08392
ChEMBL	CHEMBL32350
Chemical data
Formula	C15H18N2
Molecular mass	226.32 g/mol
	SMILES CC1=CC2=C(C=C1)N3CCNC4C3=C2CCC4 ;

Pirlindole (Lifril, Pyrazidol) is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant.^[1]^:337 It is structurally and pharmacologically related to metralindole.

References[edit]

^ Medvedev AE, et al. The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding. Chapter 36 in MAO - The Mother of all Amine Oxidases (Journal of Neural Transmission. Supplementa). Eds Finberg JPM, Youdim MBH, Riederer P, Tipton KF. Special edition of Journal of Neural Transmission, Suppl. 52 1st ed. 1998 ISBN 978-3211830376

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.